Dren Bio, a privately held, clinical-stage biotechnology company, has a new collaboration with Sanofi SA (NASDAQ:SNY) . The new agreement is built on the existing relationship between the two companies, following Sanofi’s acquisition earlier this year of Dren Bio’s DR-0201 program for deep B-cell depletion. • Sanofi shares are experiencing downward pressure. Why are SNY shares declining?The collaboration covers the discovery and development of a next-generation B-cell depleting therapy for the treatment of ...